US equities |
NVDA $176.95 ▼-5.19% AMD $503.22 ▲+12.07% MU $727.12 ▲+5.38% SPCX $141.24 ▲+5.19% SNDK $882.34 ▲+5.66% AMZN $268.08 ▲+3.39% TSLA $377.14 ▲+5.28% META $642.68 ▲+5.33%
FinancialContent

Delcath Systems, Inc. - Common Stock (NQ:DCTH)

19.12 +4.19 (+28.06%)
Delayed Quote Updated: 1:16 PM EST, Nov 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Delcath Systems, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Delcath Systems Reports Third Quarter 2026 Results and Business Highlights
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems to Participate in Upcoming Investor Conferences
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems to Host Third Quarter 2026 Earnings Call
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Highlights Clinical Program Presentations at ESMO Congress 2026 and Independent Data on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems to Participate in Upcoming Investor Conferences
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Reports Second Quarter 2026 Results and Business Highlights
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems to Participate at the Canaccord Genuity 46th Annual Growth Conference
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems to Host Second Quarter 2026 Earnings Call
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Reports First Quarter 2026 Results and Business Highlights
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems to Host First Quarter 2026 Earnings Call
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Reports Fourth Quarter and Full Year 2025 Results
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Delcath Systems, Inc.
Via Business Wire
< Previous 1 2 3 Next >